## Abstract ## Purpose To determine the diagnostic value of a new ultrasmall superparamagnetic iron oxide Clariscan®, (NC100150) for the evaluation of renal perfusion in an animal model using a 3D‐FFE‐EPI sequence. ## Materials and Methods Four groups of four rabbits each were imaged after bolus
Quantification of renal perfusion using an intravascular contrast agent (part 1): Results in a canine model
✍ Scribed by Silke Aumann; Stefan O. Schoenberg; Armin Just; Karen Briley-Saebo; Atle Bjørnerud; Michael Bock; Gunnar Brix
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 924 KB
- Volume
- 49
- Category
- Article
- ISSN
- 0740-3194
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
In this work absolute values of regional renal blood volume (rRBV) and flow (rRBF) are assessed by means of contrast‐enhanced (CE) MRI using an intravascular superparamagnetic contrast agent. In an animal study, eight foxhounds underwent dynamic susceptibility‐weighted MRI upon injection of contrast agent. Using principles of indicator dilution theory and deconvolution analysis, parametric images of rRBV, rRBF, and mean transit time (MTT) were computed. For comparison, whole‐organ blood flow was determined invasively by means of an implanted flow probe, and the weight of the kidneys was evaluated postmortem. A mean rBV value of 28 ml/100 g was found in the renal cortex, with a corresponding mean rBF value of 524 ml/100 g/min and an average MTT of about 3.4 s. Although there was a systematic difference between the absolute blood flow values determined by MRI and the ultrasonic probe, a significant correlation (r~s~ = 0.72, P < 0.05) was established. The influence of the arterial input function (AIF), T~1~ relaxation effects, and repeated measurements on the precision of the perfusion quantitation is discussed. Magn Reson Med 49:276‐287, 2003. © 2003 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract ## Purpose To evaluate the diagnostic and prognostic potential of a new protein‐binding contrast medium, B22956/1, for quantitatively characterizing tumor microvessels by MRI and monitoring response to antiangiogenic therapy. ## Materials and Methods Dynamic contrast‐enhanced MRI (DC